Asia Fresh News

Asia Fresh Stories

Archive for December 11th, 2012

Sanofi Pasteur Launches IMOJEV(R) First Single-dose Vaccine Against Japanese Encephalitis in Australia

leave a comment »

MELBOURNE, Australia/PRNewswire/ —
– About 3 billion people living in Asia Pacific and travellers to the region are at risk of Japanese encephalitis –
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that IMOJEV® vaccine against Japanese encephalitis (JE) is now available in Australia. IMOJEV® is the first single dose vaccine against JE for adults in Australia. For children, one dose of IMOJEV is recommended for primary immunization; the addition of a booster dose to extend the duration of protection is being assessed by Australian Health Authorities. IMOJEV® vaccine is licensed in Australia for people from 12 months of age and older.
About 3 billion people in the Asia Pacific Region are at risk of JE[1] for which there is no specific treatment[2]. In 1995 the first outbreak in Australia was identified in the islands of the Torres Strait[3]. More recently outbreaks have also occurred in Northern Queensland. JE is the leading cause of childhood viral neurological infection and disability in Asia. JE is also a potential risk for travellers to endemic areas. Over 1.5 million Australians travel to JE endemic countries of the Asia Pacific region[4].
“IMOJEV® has shown to provide seroprotection to over 90% adults just 2 weeks after vaccination with one dose which provides strong motive to be vaccinated before traveling[5],” said Joseph Torresi MD, Head of Travel Medicine at the Austin Hospital. “There is no specific treatment for JE and vaccination is the most effective way to be protected.”
The Australian health authorities granted marketing authorization to IMOJEV® vaccine based on the review of clinical studies involving over 4,000 children and adults which demonstrated the safety of IMOJEV® vaccine and its ability to generate a protective immune response with one dose.
“IMOJEV® is an innovative vaccine that confers high-level protection against Japanese encephalitis with just one dose,” said Russell Jacobson, General Manager of Sanofi Pasteur in Australia. “IMOJEV® makes scheduling a trip in the Asia Pacific region, or other endemic areas, more convenient for business travellers, tourists and the military alike.”
About IMOJEV® vaccine
IMOJEV® vaccine is a live-attenuated JE vaccine indicated for active immunization of people 12 months and older. The clinical data supporting the use of IMOJEV® in children and in adults have been generated in multi-center studies conducted in the United States, Australia, Thailand, and the Philippines with more than 2,400 adults and 2,200 children receiving IMOJEV®. The safety and immunogenicity of IMOJEV® were compared to a licensed JE vaccine (JE-VAX®) and placebo in adults and to a control vaccine in children. A pivotal Phase III study in adults showed that a single dose of IMOJEV® is as immunogenic as three doses of JE-VAX®. A single administration of IMOJEV® elicited a protective level of neutralizing antibodies in approximately 93% and 99% of adults 14 days and 28 days after vaccine administration, respectively[5]. Over 84% of adults were still seroprotected 5 years after vaccination [6]. A Phase III study in children showed that approximately 95% of JE virus naive subjects were seroprotected 28 days after a single dose of IMOJEV®[7]. The vaccine was well tolerated and there was no indication during the clinical development program of any safety concerns. The frequency of local and systemic reactions was comparable to those reported after administration of a placebo or a control vaccine.
About Japanese encephalitis
JE is caused by a virus transmitted by mosquitoes. The disease is neuro invasive with inflammation of the brain and its membranes (meninges). Most JE virus infections are mild (fever and headache) or without apparent symptoms, but up to 1 to 200 infections results in severe disease characterized by rapid onset of high fever, headache, neck stiffness, disorientation, coma, seizures, spastic paralysis and death. The case fatality rate is 30-35% among those with disease symptoms with over 15,000 deaths per year[8]; 50% of those who survive suffer from lasting damage to the central nervous system. In areas where the JE virus is common, encephalitis occurs mainly in young children[9].
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us
1. Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009; 15:1-7.
2. Japanese encephalitis. WHO Initiative for Vaccine Research http://www.who.int/vaccine_research/diseases/vector/en/index1.html
3. Hanna JN, Ritchie SA, Phillips DA, et al. Japanese encephalitis in north Queensland, Australia, 1998. Medical Journal of Australia 1999; 170:533-6.
4. Australian Social Trends September 2010 Australian bureau of statistics catalogue no. 4102.0
5. Torresi J, McCarthy K, Feroldi E, et al. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 2010; 28:7993-8000.
6. Nasveld PE, Ebringer A, Elmes N, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 2010; 6:1038-46.
7. Feroldi E, Pancharoen C, Kosalaraksa P, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: Randomized, controlled phase 3 immunogenicity and safety trial. Human Vaccines & Immunotherapeutics 2012; 8:929-37.
8. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89:766-74E
9. United Nations. The United Nations urbanization prospects: the 2005 revision. POP/DB/WUP/Rev.2005/1/F1. New York: United Nations; 2005.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Contacts:

Global Media Relations
Pascal Barollier
T. +33-4-37-37-50-38
pascal.barollier@sanofipasteur.com
http://www.sanofipasteur.com

Australia Media Relations
Alan Brindell
T. +61-2-8666-2362
alan.brindell@sanofi.com
http://www.sanofipasteur.com.au
Source: Sanofi Pasteur

Written by asiafreshnews

December 11, 2012 at 3:08 pm

Posted in Uncategorized

Tagged with

Globally Revolutionary New Retail Concept Unveiled at Bangkok’s Siam Center

leave a comment »

US$60 million investment in Siam Center by Siam Piwat and 200 brand owners is biggest collaborative initiative in retail development ever undertaken in Thailand that aims to lift the stature of Bangkok as top global shopping destination
“We are pioneering a revolutionary new retail development concept where the developer works with retailers and brand owners to give the entire venue a consistent visual identity as well as a consistent promise to the visitor” – Mrs. Chadatip Chutrakul – CEO, Siam Piwat Ltd.
BANGKOK /PRNewswire/ — Siam Piwat, the owner and operator of Siam Paragon and Siam Center recently unveiled sweeping plans, as part of its total rejuvenation of Siam Center, for the introduction of a revolutionary new retail concept that promises to put Bangkok among the ranks of the world’s most innovative shopping destinations when it opens on January 11th, 2013.
Mrs. Chadatip Chutrakul, CEO of Siam Piwat Co., Ltd., the owner and operator of Siam Center, said, “We’re pioneering a revolutionary new retail development concept where the developer works collaboratively with retailers and brand owners to give the entire venue a consistent visual identity. Brand owners and retailers have agreed to conceive their store designs to reflect an overall theme that is clearly and distinctly Siam Center, even for the stores of the biggest of big-name international and local brands in fashion as well as in food and beverages.”
“Brand owners and retailers are also collaborating with us to ensure the delivery of a consistent promise to the visitor: that, no matter which store one visits, or whichever restaurant one patronizes, one will meet with unexpected products and services, and which will be unlike anything available at any other venue,” she said.
In addition, most stores will carry special product selections that are only available at Siam Center, even including exclusive offerings in the food and beverage outlets.
“Big, fast-forward international brands have also agreed to present their latest new-arrival collections in Siam Center before they are presented at other branch,” Mrs. Chutrakul said.
“Siam Piwat is investing more US$ 60 million, while retailers and brand owners are investing US$ 33 million to create the new Siam Center. It is the biggest collaboration ever undertaken by retailers and brand owners in Thailand,” she said.
The SoHo district of New York is one of the inspirations behind what Siam Center is about to offer. It is, perhaps, the only place in the world where stores have designed their shops to suit the distinct style of the district, adapting themselves to fit the unique character of their environment while still preserving all that makes their brands special. For the first time, at Siam Center, all of these are now being done under one roof.
Siam Center has a gross floor area of 40,000 sqm and is located at the crossover station between the city’s two major overhead mass transit rail system routes. It is also at the heart of Bangkok’s retail zone with visitor traffic of around 150,000 people per day, of which approximately 60% are local residents and 40% tourists.
For further information, please contact:
Siam Piwat Co., Ltd.:
Sireetorn Niyomsen
Tel: +662-658-1000 ext 234
Bangkok Public Relations Ltd.:
Pairoj Pachanapreeda
Tel: +662-664-9500 ext 115
Source: Siam Piwat Co., Ltd.

Written by asiafreshnews

December 11, 2012 at 12:04 pm

Abbey Spanier Rodd & Abrams, LLP Announces Notification of Jury Verdict in Vivendi Universal, S.A. Securities Litigation and Commencement of Claims Procedure for Class Members Who Acquired Vivendi American Depository Shares (ADSs)

leave a comment »

NEW YORK /PRNewswire/ — The following statement is being issued by Abbey Spanier Rodd & Abrams, LLP regarding the Vivendi Universal, S.A. Securities Litigation.
UNITED STATES DISTRICT COURT, SOUTHERN DISTRICT OF NEW YORK
IN RE VIVENDI UNIVERSAL, S.A. SECURITIES LITIGATION, Civil Action, No. 02 Civ. 5571, (SAS/HBP) ECF Case
SUMMARY NOTICE TO CLASS MEMBERS
To: All persons from the United States, France, England and the Netherlands who purchased or otherwise acquired American Depositary Shares (“ADSs” or “ADRs”) of Vivendi Universal, S.A., (“Vivendi”) between October 30, 2000 and August 14, 2002 (“Class Members”).
This is a Court-approved notification of the jury verdict holding defendant Vivendi liable in this case. The jury verdict also found that two former senior officers of Vivendi, Jean-Marie Messier and Guillaume Hannezo, did not violate the securities laws and are not liable on any of the claims asserted against them. If you are a Class Member, you are entitled to file a claim for damages. The deadline for filing of claims is May 9, 2013. You may obtain a Claim Form and other information at http://www.vivendiclassaction.com or by calling 1-800-767-2840 toll-free. Vivendi will appeal the jury verdict and other aspects of the case, and the result is not final.
Attorneys for the plaintiffs (“Class Counsel”) intend to file an application for an award of attorneys’ fees and reimbursement of their nontaxable costs and expenses, to be paid out of the damages awarded to Class Members. Only amounts approved by the Court will be awarded. Class Counsel will request an award of attorneys’ fees of up to one-third of the amount of any damages and prejudgment interest payable to the Class. The Court will set a hearing on the application after the conclusion of the claims procedure. Relevant deadlines, the hearing date, and other documents will be posted at http://www.vivendiclassaction.com.
Clerk of Court
Source: Abbey Spanier Rodd & Abrams, LLP

Written by asiafreshnews

December 11, 2012 at 11:01 am

Posted in Uncategorized

ZMDI, a Global Semiconductor Company, Announces the Release of the ZSPM4551, a Smart Charger for Lithium-Ion Batteries

leave a comment »

DRESDEN, Germany /PRNewswire/ — ZMD AG (ZMDI), a Dresden-based semiconductor company that specializes in enabling energy-efficient solutions, today announces the release of the ZSPM4551, a DC/DC synchronous switching lithium-ion (Li-ion) battery charger. As a global supplier of analog and mixed-signal solutions for automotive, industrial, medical, information technology and consumer applications, ZMDI focuses on developing families of compact and high-efficiency products including the ZSPM4551.
The ZSPM4551 is configurable for termination voltage, charge current and additional variables to allow optimum charging conditions for a wide range of Li-ion batteries. Its 1MHz switching frequency enables the use of small filter components, resulting in smaller board space and reduced system costs.
The ZSPM4551 has an integrated I2C™ (trademark of NXP) interface, which enables the user to set application-specific temperature-compensated termination voltages and control charging currents. It can regulate up to 1.5A continuous drive current.
The ZSPM4551 features integrated power switches, internal compensation and fault protection. It offers Li-ion-specific protection for over-current, over-temperature, battery (VBAT) over-voltage and charging timeout. It includes supervisory reporting through the NFLT (inverted fault) open-drain output for interfacing with other components in the system.
The ZSPM4551 is in a league of its own when it comes to its high level of integration, up to 92% efficiency with typical loads and ultra-low power consumption. When the regulator is disabled, the device typically draws 10µA quiescent current.
“ZMDI is committed to developing advanced high-efficiency solutions to meet our customers’ variety of needs. Our smart charger, the ZSPM4551, supports our customers’ direction into portable applications, and this product is another example of ZMDI’s commitment to providing the very best solutions for our energy-conscious customers,” stated Edward Lam, Vice President of Product Marketing and Business Development at ZMDI.
Smart Charger Features:
1.5A continuous output current
VBAT reverse-current blocking
Programmable temperature-compensated termination voltage
User-programmable charging current
VBAT over-voltage and charging-timeout supervisor for VBAT reported at the NFLT pin
Input supply under-voltage lockout
Full protection for over-current and over-temperature
Charge status indication
I2C™ program interface with EEPROM registers
Temperature (junction) range -40°C to 125°C
Package: 16-L PQFN (4mm x 4mm)
Availability & Pricing
USD1.65/Euro 1.22 @ 1Ku
About ZMDI
Zentrum Mikroelektronik Dresden AG (ZMDI) is a global supplier of analog and mixed-signal semiconductors solutions for automotive, industrial, medical, information technology and consumer applications. These solutions enable our customers to create the most energy-efficient products in power management, lighting and sensors.
For over 50 years ZMDI has been globally headquartered in Dresden, Germany. With over 320 employees worldwide ZMDI serves its customers with sales offices and design centers throughout Germany, Italy, Bulgaria, France, United Kingdom, Ireland, Japan, Korea, Taiwan and the United States.
See more at http://www.zmdi.com.
For further information:
Daniel Aitken, ZMDI Global Director of Corporate Marketing and Communications, T +001-514-831-6722 daniel.aitken@zmdi.com
The URL for this news release is http://www.zmdi.com/news/press-releases-news/
Source: ZMDI

Written by asiafreshnews

December 11, 2012 at 10:34 am

Posted in Uncategorized

Tagged with

Sunshine Oilsands Announces Grant of Share Options

leave a comment »

HONG KONG /PRNewswire/ — The board of directors (the “Board”) of Sunshine Oilsands Ltd. (the “Corporation” or “Sunshine”, HK: 2012) today is pleased to announce that share options (the “Share Options”) to subscribe for shares in the capital of the Company (the “Shares”) were granted by the Corporation under its share option scheme adopted on January 26, 2012 to certain directors and eligible officers and employees of the Corporation (the “Grantees”), subject to acceptance by the Grantees, with details as follows:

Date of grant

:

December 10, 2012 (Hong Kong)
December 9, 2012 (Calgary)

Number of Shares in respect of which the Share Options were granted

:

36,054,908

Exercise prices of Share Options granted

:

Exercise prices range from HK$2.99 to HK$6.30 per Share
The average exercise price of the Share Options is HK$3.83 per Share

Closing price of the Shares on December 7, 2012

:

HK$ 2.67 (HKEx)
CAD 0.345 (TSX)

Closing price of the Shares on December 10, 2012 Morning Session

:

HK$2.83 (HKEx)

Validity period of the Share Options

:

Five (5) years

Included in the total Share Options granted are the following share options granted to directors and the Chief Executive Officer of the Corporation:
Name

Position*

Number of share
options Granted

Average
Exercise
Price

John Empey Zahary

President & CEO

4,500,000

HK$ 2.99

Michael John Hibberd

Director & Co-Chairman

4,610,000

HK$ 5.14

Songning Shen

Director & Co-Chairman

4,610,000

HK$ 5.14

Hok Ming Tseung

Director

360,000

HK$ 5.20

Haotian Li

Director

360,000

HK$ 5.20

Raymond Shengti Fong

Director

360,000

HK$ 5.20

Wazir Chand Seth

Director

360,000

HK$ 5.20

Gerald Franklin Stevenson

Director

360,000

HK$ 5.20

Gregory George Turnbull

Director

360,000

HK$ 5.20

Robert John Herdman

Director

360,000

HK$ 5.20

Other than the Chief Executive Officer and directors listed above, no substantial shareholder, chief executive, director or associate (as defined under the Listing Rules) of any of them were granted Share Options.
Pursuant to Rule 17.04(1) of the Listing Rules, the grant of the Share Options to each of the Chief Executive Officer and the directors listed above have been approved by the independent non-executive directors of the Corporation (excluding independent non-executive directors who are Grantees).
About Sunshine Oilsands Ltd.
Sunshine Oilsands Ltd. is one of the largest non-partnered holders of oil sands leases by area in the Athabasca oil sands region, which is located in the province of Alberta, Canada. Since the Company’s incorporation on 22 February 2007, Sunshine has secured over 464,897 hectares (1,148,785 acres) of oil sands leases (equal to approximately 7% of all granted leases in this area).
The Company’s principal operations are the exploration, development and production of its diverse portfolio of oil sands leases. Its principal operating regions in the Athabasca area are at West Ells, Thickwood, Legend Lake, Harper, Muskwa, Goffer, Pelican and Portage. Sunshine’s oil sands leases are grouped into three main asset categories: clastics, carbonates and conventional heavy oil.
For further enquiries, please contact:
Sunshine Oilsands Ltd.

Mr. John Zahary

Mr. David Sealock

President & CEO

Executive VP, Corporate Operations

Tel: +1-403-984-1446

Email: investorrelations@sunshineoilsands.com

Website: http://www.sunshineoilsands.com

Source: Sunshine Oilsands Ltd.

Written by asiafreshnews

December 11, 2012 at 10:02 am